Merck & Company Inc (MRK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $356.13B
Last updated: Nov 17, 2026 at 4:43 PM ET
Merck & Company Inc (MRK) Statistics
Merck & Company (MRK) has a market cap of $356.13B and an enterprise value of $400.36B. Its trailing P/E of 46.0x is above its 10-year median of 15.3x. Its return on invested capital of 3.14% compares with a 13.95% median across 11 similar companies.
Total Valuation
Enterprise value is 12.42% above the market cap, as debt exceeds cash.
| Market Cap | $356.13B |
|---|---|
| Enterprise Value | $400.36B |
| Latest price (Nov 17, 2026) | $143.39 |
Key Dates
The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Sep 15, 2026.
| Next Earnings Date | Feb 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Last Ex-Dividend Date | Sep 15, 2026 |
| Last Payment Date | Oct 7, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.2x and 7.9x. Its year-end P/E ranged from 11.7x to 72.7x from 2016 to 2025.
| P/E Ratio | 46.0x |
|---|---|
| Forward P/E | 50.9x |
| P/S Ratio | 5.2x |
| Forward P/S | 5.3x |
| P/B Ratio | 7.9x |
| P/FCF Ratio | 24.0x |
| P/OCF Ratio | 19.0x |
| PEG Ratio | 18.3 |
Enterprise Valuation
Counting debt and cash, the company is valued at 32.9x EBITDA and 27.0x free cash flow.
| EV / Earnings | 163.4x |
|---|---|
| EV / Sales | 5.9x |
| EV / EBITDA | 32.9x |
| EV / EBIT | 84.1x |
| EV / FCF | 27.0x |
Price Statistics
The stock is up 56.77% over 52 weeks and trades 1.69% below its 50-day average.
| Beta (1Y) | 0.25 |
|---|---|
| 52-Week Change | +56.77% |
| 1-Month Change | -0.17% |
| 3-Month Change | -5.23% |
| 6-Month Change | +27.19% |
| 5-Year Change | +69.81% |
| 10-Year Change | +154.63% |
| Total Return (1Y) | +60.49% |
| Total Return (3Y CAGR) | +14.48% |
| Total Return (5Y CAGR) | +14.34% |
| Return vs SPY (1Y) | +39.50% |
| Max Drawdown (1Y) | -11.89% |
| Max Drawdown (3Y) | -43.45% |
| Sharpe Ratio (1Y) | 1.41 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $145.85 |
| 200-Day Average | $128.09 |
| 52-Week Range | $91.22 to $156.00 |
| RSI (14 Days) | 45.0 |
| Average Volume (20 Days) | 9.43M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.35x current liabilities, and total debt is 1.20x shareholder equity.
| Current Ratio | 1.35x |
|---|---|
| Quick Ratio | 1.14x |
| Debt / Equity | 1.20x |
| Debt / EBITDA | 4.44x |
| Debt / FCF | 3.65x |
Returns and Efficiency
Return on invested capital is 3.14% over the last 12 months, against a 5-year average of 15.28%.
| Return on Equity (ROE) | 5.46% |
|---|---|
| Return on Assets (ROA) | 1.85% |
| Return on Invested Capital (ROIC) | 3.14% |
| Return on Capital Employed (ROCE) | 4.58% |
| ROE (5Y Average) | 27.69% |
| ROA (5Y Average) | 10.80% |
| ROIC (5Y Average) | 15.28% |
| Asset Turnover | 0.51x |
| Inventory Turnover | 3.08x |
| Receivables Turnover | 5.32x |
| Cash Conversion Cycle | 102 days |
Taxes
Income tax took 48.55% of pretax income over the last 12 months.
| Income Tax (TTM) | $2.31B |
|---|---|
| Effective Tax Rate | 48.55% |
Scores
MRK has an Altman Z-Score of 3.83, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.83 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $67.38B over the last 12 months is up 4.89% from the 12 months before.
| Revenue | $67.38B |
|---|---|
| Revenue Growth (YoY) | +4.89% |
| Gross Profit | $48.34B |
| Operating Income | $5.46B |
| Pretax Income | $4.76B |
| Net Income | $2.45B |
| EBITDA | $12.11B |
| EBIT | $4.76B |
| Reported EPS (TTM) | $3.12 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 33.81% of the $132.77B in total assets.
| Cash and Equivalents | $9.55B |
|---|---|
| Total Debt | $53.78B |
| Net Debt | $44.23B |
| Net Debt Per Share | $17.94 |
| Working Capital | $10.14B |
| Shareholder Equity | $44.89B |
| Book Value Per Share | $18.21 |
| Tangible Book Value | -$1.53B |
| Total Assets | $132.77B |
| Total Liabilities | $87.83B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.96B of capital spending, operating cash flow left $14.75B of free cash flow.
| Operating Cash Flow | $18.70B |
|---|---|
| Capital Expenditures | $3.96B |
| Free Cash Flow | $14.75B |
| FCF Per Share | $5.98 |
| Depreciation and Amortization | $7.34B |
| Dividends Paid | $8.37B |
| Share Repurchases | $3.54B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 8.10%, against a 5-year average of 24.72%.
| Gross Margin | 71.75% |
|---|---|
| Operating Margin | 8.10% |
| Pretax Margin | 7.07% |
| Net Margin | 3.64% |
| EBITDA Margin | 17.97% |
| EBIT Margin | 7.07% |
| FCF Margin | 21.89% |
| Gross Margin (5Y Average) | 73.39% |
| Operating Margin (5Y Average) | 24.72% |
| Net Margin (5Y Average) | 21.34% |
Growth
Revenue grew 3.12% a year over 3 years, and EPS 6.24% a year.
| Revenue Growth (3Y CAGR) | +3.12% |
|---|---|
| Revenue Growth (5Y CAGR) | +9.38% |
| EPS Growth (3Y CAGR) | +6.24% |
| EPS Growth (5Y CAGR) | +8.63% |
| FCF Growth (3Y CAGR) | -5.63% |
| FCF Growth (5Y CAGR) | +31.13% |
| Operating Income Growth (3Y CAGR) | +5.74% |
| Book Value Per Share Growth (2Y CAGR) | +19.88% |
Dividends and Yields
MRK pays out 44.82% of earnings as dividends.
| Dividend Per Share (Annual) | $3.40 |
|---|---|
| Dividend Yield | 2.37% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +5.42% |
| Dividend Growth (5Y CAGR) | +5.75% |
| Payout Ratio | 44.82% |
| FCF Payout Ratio | 56.73% |
| Earnings Yield | 2.17% |
| FCF Yield | 4.17% |
| Buyback Yield | 1.00% |
| Shareholder Yield | 3.37% |
Stock Splits
The last split was a 2-for-1 forward split on Feb 17, 1999.
| Last Split Date | Feb 17, 1999 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, MRK has the highest P/E.
P/E RatioPeer median 19.8x
P/S RatioPeer median 5.0x
ROICPeer median 13.95%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.17%
Dividend YieldPeer median 2.68%
| P/E Ratio | 46.0x vs 19.8x median |
|---|---|
| P/S Ratio | 5.2x vs 5.0x median |
| ROIC | 3.14% vs 13.95% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.89% vs +7.17% median |
| Dividend Yield | 2.37% vs 2.68% median |
Analyst Forecast
Consensus estimates put revenue growth at 3.37% and EPS growth at 0.06% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3.37% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +0.06% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MRK
What is MRK's market cap?
Merck & Company has a market cap of $356.13B. Its enterprise value, which adds debt and subtracts cash, is $400.36B.
What is MRK's P/E ratio?
Merck & Company has a trailing P/E ratio of 46.0x and a forward P/E of 50.9x.
How many shares of MRK are outstanding?
Merck & Company has 2.47B shares outstanding. The count is down 0.68% from a year earlier.
Does MRK pay a dividend?
Yes. Merck & Company pays $3.40 a share a year, a dividend yield of 2.37%.
How much debt does MRK have?
Merck & Company has $53.78B of total debt and $9.55B of cash and equivalents, a net debt position of $44.23B.
MRK pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts